title: Treating telangiectasias: my method.
abstract: OBJECTIVE
  The authors propose a new classification of telangiectasias: conditions involving demonstrated reflux are classified as type A telangiectasias; clustered, spider telangiectasias not related to reflux and with vein diameters of >0.2 mm are classified as type B, while isolated telangiectatic veins of ≤0.2 mm diameter are classed as type C. This histological and pathophysiological approach is the basis for the Authors' Multi-Therapy Treatment Protocol (MTT).
  
  
  METHODS
  The treatment regimen provides for initial treatment of type A telangiectasias with just conventional reflux sclerotherapy, followed three weeks later by treatment of type B telangiectasias with 0.25-0.5% polidocanol foam, associated with both external compression and tumescent vasoconstriction (START technique). This is then followed after a further three months by dermal stimulation with mesoglycan (LIDS technique) to reinforce the district underlying the type C telangiectasias. The MTT Protocol was used on 63 patients (125 limbs). A 12-month follow-up showed the treatment regimen to provide better aesthetic and functional results than classical sclerotherapy, with few adverse effects and greater patient satisfaction.
authors.affiliation: Studio Flebologico Ferrara, Naples, Italy. frferr@tiscali.it
authors.forename: F
authors.initials: F
authors.lastname: Ferrara
authors.forename: G
authors.initials: G
authors.lastname: Ferrara
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000627:therapeutic use; D018056:Hemorheology; D006801:Humans; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D018579:Patient Selection; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D012501:Saphenous Vein / Q000503:physiopathology; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D015911:Sclerotherapy / Q000379:methods*; D053828:Stockings, Compression; D013684:Telangiectasis / Q000145:classification / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D014463:Ultrasonography; D014648:Varicose Veins / Q000628:therapy; D055682:Viscoelastic Substances; D055815:Young Adult
chemical_list: D006025:Glycosaminoglycans; D012597:Sclerosing Solutions; D055682:Viscoelastic Substances; D000077423:Polidocanol; D011092:Polyethylene Glycols; C040617:mesoglycan